Results - Announcements
Shukra Pharmaceuticals Ltd share price declined by 0.14% to Rs 79.85 after the company's net profit softened by 1.93% to Rs 12.71 crore, while revenue from operations gained significantly 87.93% to Rs 44.2 crore in Q3FY26 over Q2FY26.
The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 27.82 lakh crore, rising 5.14%. It has marginally improved by 2.03% over last one week and crept higher by 1.77% in last one month while the market capitalization of Shukra Pharmaceuticals Ltd has improved by 6.48% and 105.89% in the same period respectively.
Profit before tax (PBT) of Shukra Pharmaceuticals Ltd stood at Rs 17.83 crore in Q3 FY26, expanding by 8815.00% year-on-year, and slipping 1.87% quarter-on-quarter. EBITDA came in at Rs 18 crore, tanking 951.64% YoY and declining 2.47% sequentially.
Total expenses surged 387.55% to Rs 26.62 crore in Q3FY26 over Q3FY25. During the quarter, cost of materials consumed stood at Rs 15.99 crore, soaring by 1179.20% YoY, while employee benefits expense was at Rs 4.26 crore, dipping slightly 2.96% YoY.
For the TTM ended FY26, revenue from operations soared by 74.07% to Rs 56.73 crore, while net profit jumped 130.27% to Rs 22.06 crore, compared to previous TTM. EBITDA jumped by 795% to Rs 24.16 crore, and PBT witnessed a strong rise of 115.82% to Rs 28.79 crore compared to previous TTM.
The company's consolidated net cash flow from operating activities stood at Rs 3.93 crore in FY26, as against Rs 7.92 crore in FY25.
Shukra Pharmaceuticals Ltd rallied 102.72% in last one year, significantly outperforming the benchmark BSE Sensex which has eased by 7.38% during the same period.